25-Hydroxyvitamin D levels, race, and the progression of kidney disease

Journal of the American Society of Nephrology

Volumn 20, Issue 12, 2009, Pages 2631-2639

  Melamed, Michal L ^a   Astor, Brad ^b   Michos, Erin D ^c   Hostetter, Thomas H ^a   Powe, Neil R ^d   Muntner, Paul ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ETHNICITY; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOCIOECONOMICS;

EID: 72049115797     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009030283     Document Type: Article

References (57)

1. Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, Brancati FL: Excess risk of chronic kidney disease among African-American versus white subjects in the united states: A population-based study of potential explanatory factors. J Am Soc Nephrol 13: 2363-2370, 2002 (Pubitemid 34925247)
2. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49: 1063-1069, 2007 (Pubitemid 351664326)
3. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B: The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 30: 980-986, 2007
4. Melamed ML, Muntner P, Michos ED, Uribarri J, Weber C, Sharma J, Raggi P: Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: Results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 28: 1179-1185, 2008
5. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511, 2008
6. Giovannucci E, Liu Y, Hollis BW, Rimm EB: 25-Hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med 168: 1174-1180, 2008 (Pubitemid 351831400)
7. Melamed ML, Michos ED, Post W, Astor B: 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168: 1629-1637, 2008
8. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J: Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89-90: 387-392, 2004 (Pubitemid 38844316)
9. Migliori M, Giovannini L, Panichi V, Filippi C, Taccola D, Origlia N, Mannari C, Camussi G: Treatment with 1,25-dihydroxyvitamin D3 preserves glomerular slit diaphragm-associated protein expression in experimental glomerulonephritis. Int J Immunopathol Pharmacol 18: 779-790, 2005
10. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, Doi T: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 158: 1733-1741, 2001 (Pubitemid 32422938)
11. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS: 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 50: 69-77, 2007 (Pubitemid 46962855)
12. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358-363, 1995
13. Chan JC, Kodroff MB, Landwehr DM: Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure. Pediatrics 68: 559-571, 1981
14. Coen G, Mazzaferro S, Manni M, Fondi G, Perruzza I, Pasquali M, Taggi F: No acceleration and possibly slower progression of renal failure during calcitriol treatment in predialysis chronic renal failure. Nephrol Dial Transplant 9: 1520, 1994 (Pubitemid 24310304)
15. Zadshir A, Tareen N, Pan D, Norris K, Martins D: The prevalence of hypovitaminosis D among us adults: Data from the NHANES III. Ethn Dis 15: S5-97-S5-101, 2005 (Pubitemid 41824441)
16. Dawson-Hughes B: Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. Am J Clin Nutr 80: 1763S-1766S, 2004
17. Loomis WF: Skin-pigment regulation of vitamin-D biosynthesis in man. Science 157: 501-506, 1967
18. Clemens TL, Adams JS, Henderson SL, Holick MF: Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1: 74-76, 1982
19. Reis JP, Michos ED, von Muhlen D, Miller ER 3rd: Differences in vitamin D status as a possible contributor to the racial disparity in peripheral arterial disease. Am J Clin Nutr 88: 1469-1477, 2008
20. Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27: 2813-2818, 2004 (Pubitemid 39565042)
21. Cosman F, Morgan DC, Nieves JW, Shen V, Luckey MM, Dempster DW, Lindsay R, Parisien M: Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 12: 958-966, 1997 (Pubitemid 27225007)
22. Dawson-Hughes B, Harris SS, Finneran S, Rasmussen HM: Calcium absorption responses to calcitriol in black and white premenopausal women. J Clin Endocrinol Metab 80: 3068-3072, 1995
23. Harris SS: Vitamin D and African Americans. J Nutr 136: 1126-1129, 2006
24. Powe NR, Melamed ML: Racial disparities in the optimal delivery of chronic kidney disease care. Med Clin North Am 89: 475-488, 2005 (Pubitemid 40332393)
25. Hsu CY, Lin F, Vittinghoff E, Shlipak MG: Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the united states. J Am Soc Nephrol 14: 2902-2907, 2003 (Pubitemid 37305653)
26. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ: The excess incidence of diabetic end-stage renal disease among blacks: A population-based study of potential explanatory factors. JAMA 268: 3079-3084, 1992
27. Trivedi HS, Pang MM: Discrepancy in the epidemiology of nondiabetic chronic renal insufficiency and end-stage renal disease in black and white Americans: The Third National Health and Nutrition Examination Survey and United States Renal Data System. Am J Nephrol 23: 448-457, 2003
28. Newsome BB MW, Coffey CS, Allison JJ, Kiefe CI, Warnock DG: Survival advantage of black patients with kidney disease after acute myocardial infarction. Clin J Am Soc Nephrol 1: 993-999, 2006
29. Smith GL, Shlipak MG, Havranek EP, Masoudi FA, McClellan WM, Foody JM, Rathore SS, Krumholz HM: Race and renal impairment in heart failure: Mortality in blacks versus whites. Circulation 111: 1270-1277, 2005
30. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease study. Kidney Int 51: 1908-1919, 1997
31. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: Racial and treatment effects. The MRFIT research group. JAMA 268: 3085-3091, 1992
32. Krop JS, Coresh J, Chambless LE, Shahar E, Watson RL, Szklo M, Brancati FL: A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: The Atherosclerosis Risk in Communities study. Arch Intern Med 159: 1777-1783, 1999 (Pubitemid 29379142)
33. Hoy WE, Rees M, Kile E, Mathews JD, Wang Z: A new dimension to the Barker hypothesis: Low birthweight and susceptibility to renal disease. Kidney Int 56: 1072-1077, 1999 (Pubitemid 29411735)
34. Brenner BM, Chertow GM: Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 23: 171-175, 1994
35. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS: Myh9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185-1192, 2008
36. Branisteanu DD, Leenaerts P, van Damme B, Bouillon R: Partial prevention of active Heymann nephritis by 1 alpha, 25 dihydroxyvitamin D3. Clin Exp Immunol 94: 412-417, 1993 (Pubitemid 24005276)
37. Lemire JM, Ince A, Takashima M: 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/L mice. Autoimmunity 12: 143-148, 1992
38. Lillevang ST, Rosenkvist J, Andersen CB, Larsen S, Kemp E, Kristensen T: Single and combined effects of the vitamin D analogue KH1060 and cyclosporin A on mercuric-chloride-induced autoimmune disease in the BN rat. Clin Exp Immunol 88: 301-306, 1992
39. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E: Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53: 1696-1705, 1998 (Pubitemid 28243754)
40. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, Palla R, Tetta C, Camussi G: Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 60: 87-95, 2001
41. Hirata M, Makibayashi K, Katsumata K, Kusano K, Watanabe T, Fukushima N, Doi T: 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant 17: 2132-2137, 2002 (Pubitemid 35446668)
42. Wang Y, Zhou J, Minto AW, Hack BK, Alexander JJ, Haas M, Li YC, Heilig CW, Quigg RJ: Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int 70: 882-891, 2006 (Pubitemid 44285965)
43. Aschenbrenner JK, Sollinger HW, Becker BN, Hullett DA: 1,25(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 100: 171-175, 2001 (Pubitemid 32989358)
44. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75: 88-95, 2009
45. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002 (Pubitemid 34787360)
46. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001 (Pubitemid 34940825)
47. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C: Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86: 1633-1637, 2001 (Pubitemid 32377290)
48. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM: Ultraviolet B and blood pressure. Lancet 352: 709-710, 1998
49. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994: Series 1 - Programs and collection procedures. Vital Health Stat 1 1-407, 1994
50. Ezzati TM, Massey JT, Waksberg J, Chu A, Maurer KR: Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 2 1-35, 1992
51. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K: Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: Data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167: 1159-1165, 2007 (Pubitemid 46919818)
52. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, Levey AS: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 39: 920-929, 2002 (Pubitemid 34454210)
53. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003 (Pubitemid 38129105)
54. Zhu S, St-Onge MP, Heshka S, Heymsfield SB: Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism 53: 1503-1511, 2004 (Pubitemid 39410395)
55. International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), Washington, DC, World Health Organization, 1991
56. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Washington, DC, World Health Organization, 1992
57. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR: Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30: 771-777, 2002 (Pubitemid 34468001)